These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 19562616

  • 1. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H.
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [Abstract] [Full Text] [Related]

  • 2. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC.
    MAbs; 2014 Aug; 6(3):749-55. PubMed ID: 24594909
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanović S, Dörfel D, Schneider P, Salih HR.
    Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
    Qi J, Chen SS, Chiorazzi N, Rader C.
    Methods; 2019 Feb 01; 154():70-76. PubMed ID: 30145356
    [Abstract] [Full Text] [Related]

  • 11. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 01; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 12. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
    Dixon KJ, Snyder KM, Khaw M, Hullsiek R, Davis ZB, Matson AW, Shirinbak S, Hancock B, Bjordahl R, Hosking M, Miller JS, Valamehr B, Wu J, Walcheck B.
    Front Immunol; 2024 Mar 01; 15():1407567. PubMed ID: 39100677
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression.
    Moga E, Cantó E, Vidal S, Juarez C, Sierra J, Briones J.
    Exp Hematol; 2011 Nov 01; 39(11):1064-71. PubMed ID: 21864486
    [Abstract] [Full Text] [Related]

  • 14. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST.
    Leuk Lymphoma; 2004 Nov 01; 45(11):2269-73. PubMed ID: 15512816
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T.
    Leuk Lymphoma; 2004 Feb 01; 45(2):205-19. PubMed ID: 15101704
    [Abstract] [Full Text] [Related]

  • 16. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y, You F, Jiang L, Li J, Zhu X, Bao Y, Sun X, Tang X, Meng H, An G, Zhang B, Yang L.
    Oncotarget; 2017 Jun 06; 8(23):37128-37139. PubMed ID: 28415754
    [Abstract] [Full Text] [Related]

  • 17. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G, Klein C, Stern M.
    J Immunol; 2014 Jun 15; 192(12):5618-24. PubMed ID: 24795454
    [Abstract] [Full Text] [Related]

  • 18. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
    VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS.
    Cancer Immunol Res; 2018 Oct 15; 6(10):1150-1160. PubMed ID: 30089638
    [Abstract] [Full Text] [Related]

  • 19. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM, Hullsiek R, Mishra HK, Mendez DC, Li Y, Rogich A, Kaufman DS, Wu J, Walcheck B.
    Front Immunol; 2018 Oct 15; 9():2873. PubMed ID: 30574146
    [Abstract] [Full Text] [Related]

  • 20. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM, Shields J, Garron C, Hu Y, Boutin P, Shankara S, Weber W, Roberts B, Kaplan JM.
    Leuk Lymphoma; 2010 Jul 15; 51(7):1293-304. PubMed ID: 20377308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.